New Drug Development for Known and Emerging Viruses
Wiley-VCH (Verlag)
978-3-527-34337-9 (ISBN)
Discusses how to address the need for fighting Ebola, Zika, and other human viruses by building on the successes in antiviral therapy of the past decade
Written by leading medicinal chemists from academia and industry, this book discusses the entire field of antiviral drug discovery and development from a medicinal chemistry perspective, focusing on antiviral drugs, targets, and viral disease mechanisms. It provides an outlook on emerging pathogens such as Ebola, Zika, West Nile, Lassa, and Norovirus, and includes a chapter on the current Coronoavirus pandemic.
»New Developments in Antiviral Drugs «describes the discovery and development process for different classes of viruses and targets based on the experiences from the nine human viruses for which approved drugs are on the market (HIV, HCV, Influenza, RSV, HBV, HPV, HCMV, HSV, and VZV). It covers the properties and development potential of 20 classes of currently approved antivirals, including combination drugs, and looks at novel antiviral strategies against emerging viruses.
- Covers the entire field of antiviral drug discovery and development
- Addresses the need for antiviral drugs to combat major health threats such as Ebola, Zika, West Nile, and COVID-19
- Summarizes the successes of the past 15 years in developing ground-breaking medicines against 9 major human viruses, both from the medicinal chemistry and the pharmacological angle
- Discusses practical and strategic challenges in the drug discovery and development process, including screening technologies, latency, and toxicity issues
»New Developments in Antiviral Drugs« is an important book for medicinal chemists, pharmaceutical chemists, virologists, and epidemiologists, and will be of great interest to those in the pharmaceutical industry and public health agencies.
Prof. Helga Rubsamen-Schaeff was CEO of AiCuris since its foundation in 2006 as a spin out from the infectious disease unit of Bayer Healthcare, also previously led by her. In March 2015 she stepped down from the CEO position and has taken over the chair of AiCuris' Scientific Advisory Board. She is also a member of the scientific panel for health under the Horizon 2020 program of the EU. Before her time at Bayer, she was the scientific and executive director of the Chemotherapeutical Research Institute Georg-Speyer-Haus in Frankfurt.
A chemist by training, Prof. Rubsamen-Schaeff was awarded the venia legendi from the University of Frankfurt and has been professor of biochemistry since 1988. Her research interests focus on research and development of antiviral drugs (Herpes, cytomegalovirus, Human Immunodeficiency Virus, Hepatitis B), novel resistance-breaking antibiotics, as well as emerging infectious diseases and oncology.
Helmut Buschmann has a PhD in organic chemistry from Aachen University and extensive industrial experience in medicinal chemistry, drug discovery and development, scale-up, pharmaceutical development, CMC, patent filing and prosecution. Helmut has over 25 years of international experience in drug discovery research and drug development in the pharmaceutical/biotechnology sectors, both in industry and academia. During his career he worked with a broad range of different targets in different therapeutic areas from pain research to anti-infectives. He has a long publication and patent record, being an author/co-author in more than 150 scientific publications, editor of various reference books and is a named inventor/co-inventor in more than 250 patent applications.
As a result of his research activities more than 15 NCEs within different therapeutic areas have entered the clinical phase (e.g. Rosonabant, Cizorlitine, Dulopetine, Axamadol). Some of them have reached clinical phase III or are marketed (e.g. Tapentadol: Nucynta (R) Palexia (R)). Currently, he is Head of Chemistry, Pharmaceutical Development and Patent Affairs at AiCuris, Wuppertal and cofounder and co-owner of RD&C Research, Development & Consulting in Vienna.
HIV - Disease overview, targets for therapy and open issues
Curing Hepatitis C with Direct-Acting Antiviral Therapy
Antiviral Drugs against Influenza Virus
Respiratory Syncytial Virus Immunoreactivity, Vaccine development, and Therapeutics
Herpes simplex viruses
Antiviral strategies against the Human Cytomegalo Virus: Inhibitors of Viral Terminase
Antiviral targeting of the complex Epstein Barr virus life cycle
Kaposi's Sarcoma-associated Herpesvirus - antiviral treatment
Hepatitis B virus: HBV capsid assembly modulators (CAMs)
Hepatitis E virus - Current development in antiviral strategies
Antiviral Therapy of Adenovirus Infections
New Developments in Antiviral Drugs against ssDNA-Viruses: Human Parvovirus Infection
Antiviral targets and strategies to treat and prevent human norovirus infections
Antiviral strategies against (non-polio) picornaviruses
Novel antiviral strategies against emerging arbovirus infections
Current Therapies for Biosafety Level 4 Pathogens
Severe Acute Respiratory Syndrome (SARS) Coronavirus (SARS-CoVs) 1 and 2
| Erscheinungsdatum | 16.06.2021 |
|---|---|
| Reihe/Serie | Methods and Principles in Medicinal Chemistry |
| Mitarbeit |
Herausgeber (Serie): Raimund Mannhold, Helmut Buschmann, Jörg Holenz |
| Verlagsort | Weinheim |
| Sprache | englisch |
| Maße | 170 x 244 mm |
| Gewicht | 1140 g |
| Einbandart | gebunden |
| Themenwelt | Medizin / Pharmazie ► Pharmazie |
| Naturwissenschaften ► Biologie | |
| Naturwissenschaften ► Chemie | |
| Schlagworte | aufkommende Viren • Biowissenschaften • Chemie • Chemistry • Corona • Coronavirus-Infektion • Covid-19 • Drug Discovery & Development • Drug Discovery & Development • infectious disease • Infektionskrankheiten • Life Sciences • Medical Science • Medizin • neu auftretende Viren • SARS • Sars-2-Virus • SARS-CoV-2 • Virologie • Virology • Wirkstoffforschung • Wirkstoffforschung u. -entwicklung |
| ISBN-10 | 3-527-34337-7 / 3527343377 |
| ISBN-13 | 978-3-527-34337-9 / 9783527343379 |
| Zustand | Neuware |
| Haben Sie eine Frage zum Produkt? |
aus dem Bereich
